These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 31207169

  • 1. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, Stahl N, Yancopoulos GD, Geba GP.
    Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.
    Tiseo PJ, Kivitz AJ, Ervin JE, Ren H, Mellis SJ.
    Pain; 2014 Jul; 155(7):1245-1252. PubMed ID: 24686255
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, Junor R, Carey W, Brown MT, West CR, Verburg KM.
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [Abstract] [Full Text] [Related]

  • 5. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A, Ma C, Ahdieh H, Galer BS.
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [Abstract] [Full Text] [Related]

  • 6. Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study.
    Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J.
    Arthritis Rheumatol; 2017 Apr; 69(4):763-773. PubMed ID: 27748055
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, West CR.
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.
    Kelly KM, Sanga P, Zaki N, Wang S, Haeussler J, Louie J, Thipphawong J.
    Curr Med Res Opin; 2019 Dec; 35(12):2117-2127. PubMed ID: 31387410
    [Abstract] [Full Text] [Related]

  • 9. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR.
    Arthritis Rheum; 2013 Jul; 65(7):1795-803. PubMed ID: 23553790
    [Abstract] [Full Text] [Related]

  • 10. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC, Carrino JA, Schnitzer TJ, Guermazi A, Walsh DA, White A, Nakajo S, Fountaine RJ, Hickman A, Pixton G, Viktrup L, Brown MT, West CR, Verburg KM.
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, West CR, Verburg KM.
    Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.
    Dakin P, Kivitz AJ, Gimbel JS, Skrepnik N, DiMartino SJ, Emeremni CA, Gao H, Stahl N, Weinreich DM, Yancopoulos GD, Geba GP.
    Ann Rheum Dis; 2021 Apr; 80(4):509-517. PubMed ID: 33199274
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of E-OA-07 in moderate to severe symptoms of osteoarthritis: a double-blind randomized placebo-controlled study.
    Kulkarni MP, Shakeel A, Shinde BS, Rosenbloom RA.
    Am J Ther; 2011 Apr; 18(2):170-7. PubMed ID: 21317618
    [Abstract] [Full Text] [Related]

  • 14. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR.
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [Abstract] [Full Text] [Related]

  • 15. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
    Temple AR, Benson GD, Zinsenheim JR, Schweinle JE.
    Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
    [Abstract] [Full Text] [Related]

  • 16. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR.
    J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
    Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, Brown MT, West CR, Verburg KM.
    J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
    [Abstract] [Full Text] [Related]

  • 18. Responsiveness of the OARSI-OMERACT osteoarthritis pain and function measures.
    Bond M, Davis A, Lohmander S, Hawker G.
    Osteoarthritis Cartilage; 2012 Jun; 20(6):541-7. PubMed ID: 22425883
    [Abstract] [Full Text] [Related]

  • 19. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
    Neogi T, Hunter DJ, Churchill M, Shirinsky I, White A, Guermazi A, Omata M, Fountaine RJ, Pixton G, Viktrup L, Brown MT, West CR, Verburg KM.
    Arthritis Res Ther; 2022 Mar 29; 24(1):78. PubMed ID: 35351194
    [Abstract] [Full Text] [Related]

  • 20. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial.
    DeLemos BP, Xiang J, Benson C, Gana TJ, Pascual ML, Rosanna R, Fleming B.
    Am J Ther; 2011 May 29; 18(3):216-26. PubMed ID: 20215961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.